SEC Form SC 13G/A filed by Novavax Inc. (Amendment)

3/7/24 4:34:19 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $NVAX alert in real time by email

SC 13G/A 1 NovavaxIncNVAX.txt MS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* NOVAVAX INC ----------------------------------------------------- (Name of Issuer) Common Stock ----------------------------------------------------- (Title of Class of Securities) 670002401 ----------------------------------------------------- (CUSIP Number) February 29, 2024 ----------------------------------------------------- (Date Of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1745 (3-06) CUSIP No.670002401 13G Page 2 of 5 Pages -------------------------------------------------------------------------------- 1. NAME OF REPORTING PERSON: I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Morgan Stanley I.R.S. # 36-3145972 -------------------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP: (a) [ ] (b) [ ] -------------------------------------------------------------------------------- 3. SEC USE ONLY: -------------------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware. -------------------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER: SHARES 0 BENEFICIALLY -------------------------------------------------------------- OWNED BY 6. SHARED VOTING POWER: EACH 2,427,012 REPORTING -------------------------------------------------------------- PERSON 7. SOLE DISPOSITIVE POWER: WITH: 0 -------------------------------------------------------------- 8. SHARED DISPOSITIVE POWER: 2,454,328 -------------------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 2,454,328 -------------------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES: [ ] -------------------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 1.8% -------------------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON: HC, CO -------------------------------------------------------------------------------- CUSIP No.670002401 13G Page 3 of 5 Pages -------------------------------------------------------------------------------- Item 1. (a) Name of Issuer: NOVAVAX INC -------------------------------------------------------------- (b) Address of Issuer's Principal Executive Offices: 700 QUINCE ORCHARD ROAD, GAITHERSBURG MD 20878 UNITED STATES OF AMERICA -------------------------------------------------------------- Item 2. (a) Name of Person Filing: (1) Morgan Stanley -------------------------------------------------------------- (b) Address of Principal Business Office, or if None, Residence: (1) 1585 Broadway New York, NY 10036 -------------------------------------------------------------- (c) Citizenship: (1) Delaware. -------------------------------------------------------------- (d) Title of Class of Securities: Common Stock -------------------------------------------------------------- (e) CUSIP Number: 670002401 -------------------------------------------------------------- Item 3. If this statement is filed pursuant to Sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [ ] An investment adviser in accordance with Sections 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F); (g) [x] A parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J); (k) [ ] Group, in accordance with sections 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with sections 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Not Applicable CUSIP No.670002401 13G Page 4 of 5 Pages -------------------------------------------------------------------------------- Item 4. Ownership as of February 29, 2024.* (a) Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s). (b) Percent of Class: See the response(s) to Item 11 on the attached cover page(s). (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s). (ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s). (iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s). (iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s). Item 5. Ownership of Five Percent or Less of a Class. (1) As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities. Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of Group. Not Applicable Item 10. Certification. (1) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release. CUSIP No.670002401 13G Page 5 of 5 Pages -------------------------------------------------------------------------------- Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: March 07, 2024 Signature: /s/ Christopher O'Hara -------------------------------------------------------------------- Name/Title: Christopher O'Hara/Authorized Signatory, Morgan Stanley -------------------------------------------------------------------- MORGAN STANLEY

Get the next $NVAX alert in real time by email

Recent Analyst Ratings for

$NVAX

Date	Price Target	Rating	Analyst
7/30/2024	$8.00	Neutral → Underweight	JP Morgan
5/10/2024	$4.00 → $12.00	Underperform → Neutral	BofA Securities
5/10/2024		Underweight → Neutral	JP Morgan
8/9/2023	$15.00	Neutral → Buy	B. Riley Securities
4/20/2023	$55.00 → $10.00	Outperform → Market Perform	TD Cowen
3/1/2023	$29.00 → $10.00	Buy → Neutral	B. Riley Securities
1/9/2023	$74.00 → $37.00	Buy	B. Riley Securities
12/30/2022	$207.00 → $110.00	Buy	H.C. Wainwright

More analyst ratings

SEC Form SC 13G/A filed by Novavax Inc. (Amendment)

Chat with this insight

Recent Analyst Ratings for $NVAX

$NVAX Market Insights

Live Market Insights

Looking Into Novavax's Recent Short Interest

10 Health Care Stocks Whale Activity In Today's Session

COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch

$NVAX Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Novavax Inc.

Amendment: SEC Form SC 13G/A filed by Novavax Inc.

Amendment: SEC Form SC 13G/A filed by Novavax Inc.

$NVAX SEC Filings

Novavax Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Novavax Inc.

Novavax Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

$NVAX Financials

Live finance-specific insights

$NVAX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$NVAX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$NVAX Press Releases

Fastest customizable press release news feed in the world

$NVAX Leadership Updates

Live Leadership Updates

Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights

Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024

Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights

SEC Form 4 filed by Section 16 Draghia-Akli Ruxandra

SEC Form 3 filed by new insider Draghia-Akli Ruxandra

EVP, CCO and CBO Trizzino John converted options into 655 shares and covered exercise/tax liability with 317 shares, increasing direct ownership by 1% to 28,310 units (SEC Form 4)

Novavax downgraded by JP Morgan with a new price target

Novavax upgraded by BofA Securities with a new price target

Novavax upgraded by JP Morgan

Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

Novavax to Participate in Jefferies London Healthcare Conference

Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights

Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

Shah Capital nominates two highly qualified independent director candidates for Novavax

Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities

$NVAX FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

October 3, 2023 - FDA Authorizes Updated Novavax COVID-19 Vaccine Formulated to Better Protect Against Currently Circulating Variants

Recent Analyst Ratings for
$NVAX

$NVAX
Market Insights

$NVAX
Large Ownership Changes

$NVAX
SEC Filings

$NVAX
Financials

$NVAX
Insider Trading

$NVAX
Analyst Ratings

$NVAX
Press Releases

$NVAX
Leadership Updates

$NVAX
FDA approvals